All News

knee.calcinosis.inflammation

Frequency and Features of CPPD

Jack Cush, MD

An international cohort study of patients with calcium pyrophosphate deposition (CPPD) disease, i.e., recurrent acute CPP crystal arthritis, chronic CPP crystal inflammatory arthritis, and crowned dens syndrome (CDS) identifies both acute and chronic inflammatory phenotypes, each with distinctive clinical and imaging diagnostic features.

Read Article
RheumNow Podcast square

Pollution and Autoimmunity (7.12.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
MRI.kneepain.jpg

ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update

Jack Cush, MD

EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).

Read Article
Stop,pills,water

Can we withdraw treatment in post-menopausal osteoporosis?

EurekAlert!

Analysis of French claims data, found over half of women initiating oral bisphosphonates (BP) between 2015 and 2020 discontinued treatment for at least one year, which was associated with a 12% increase in fracture risk.

Read Article
OA, erosive, inflammatory, DIP

2023 EULAR classification criteria for hand osteoarthritis

Jack Cush, MD

A EULAR consensus group has established classification criteria for overall hand osteoarthritis (OA) and its subtypes (interphalangeal OA and thumb base OA).

The criteria require two mandatory criteria to be met:

Read Article
RheumNow Podcast square

The Window of Opportunity (5.24.2024)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?

Read Article
hip-fracture.jpg

Legal (Not So) Merry-Go-Round of Alendronate Atypical Fractures

Jack Cush, MD

Dr. Gregory Curfman, MD (Executive editor of JAMA) writes on the chronological legal progress of a lawsuit stemming from rare instances of atypical femoral fractures associated with bisphosphonate (alendronate) use.

Read Article
bone%20dense.jpg (keep)

Antacids can Diminish Bone Density

EurekAlert!

Proton pump inhibitors (PPIs), a specific class of antacid drugs, are among the most widely used medications of all. They are frequently prescribed to many groups of patients, including those with rheumatism.

Read Article
VitD_1.jpg

Consensus Statements on Vitamin D

Jack Cush, MD

The “Controversies in Vitamin D” International Conference has published their proceedings on vitamin D metabolism, assessment, actions, and supplementation. Interestingly, optimal levels of 25-hydroxy vitamin D (25(OH)D) are still being debated. 

Read Article
Elder adult Cohort study of 2413 women & 792 men w/ hip BMD-defined osteoporosis based on CT scans, shows 30% of women & 34% of men had hip Fx. Rx w/ alendronate (34%F; 24% M) signif lowered Fx rates (aOR 0.26 and 0.21, respectively) = no sex difference https://t.co/briuZAYVKx https://t.co/xrZ12TmMvM

Links:

Dr. John Cush RheumNow ( View Tweet)
Most read at Annals: Pharmacologic Treatment of Primary #Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From @ACPIMPhysicians https://t.co/wMg63aG4rB https://t.co/ZDKdHkH0fh

Links:

Annals of Int Med AnnalsofIM ( View Tweet)
RT @drminidey OP0165- incidence & risk factors of D2T RA in an early RA cohort Factors assoc with D2T RA: 🩸 Seropositivity 🦴 Erosions 📈 Disease activity 📊 D2T pts have higher steroid doses & more commonly develop iatrogenic-related #comorbidities, e.g. osteoporosis

Dr. John Cush RheumNow ( View Tweet)

Late “Breaking”: Reducing Osteoporotic Fractures in Postmenopausal Women Dr. Janet Pope discusses abstract POS0583 presented at Eular 2024 in Vienna, Austria. https://t.co/HIXV4EUkJb https://t.co/p38e6pzAvC

Links:

Dr. John Cush RheumNow ( View Tweet)
When would I use #Aclasta vs #Prolia since #denosumab has LESS #fractures ▶️younger women with #osteoporosis requiring Rx due to long safety ▶️less wearing off when stopping it ▶️noncompliant Pts as prolia reverses effect when dose is missed @RheumNow #EULAR2024 @eular_org https://t.co/0RTGx0sCTd

Links:

Janet Pope Janetbirdope ( View Tweet)

What is better for #Rx of #osteoporosis? #Denosumab or ##Zoledronic acid? #Prolia compared to #Aclasta Giant admin US data of 125,000 Rx niaive women with #OP ▶️Prolia has LESS fractures! POS0583 #EULAR2024 @eular_org @RheumNow https://t.co/eo1ny2VIRf

Links:

Janet Pope Janetbirdope ( View Tweet)
Check point inhibitors may cause bone loss and fractures. Lems W #EULAR2024 @RheumNow https://t.co/rf1AU60Eah

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
OP0165- incidence & risk factors of D2T RA in an early RA cohort Factors assoc with D2T RA: 🩸 Seropositivity 🦴 Erosions 📈 Disease activity 📊 D2T pts have higher steroid doses & more commonly develop iatrogenic-related #comorbidities, e.g. osteoporosis #EULAR24 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

The ability to predict hip fractures just went to a new level https://t.co/k9cAPIJigd A proteomic risk score was found to be strongly predictive of incident hip fractures in multiple independent populations @NatureAging https://t.co/WZemPZqsev

Links:

Eric Topol EricTopol ( View Tweet)
Lille Univ Hosp study of 485 systemic sclerosis pts, found osteoporosis in 23% (18% w/ fragility Fx). OP independently linked to age (OR1.06), topoisomerase I Ab+ positivity (OR 2.22) & GC treatment (OR 4.48) https://t.co/9KN5VQnl4A https://t.co/L7RwDdzaFZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Legal (Not So) Merry-Go-Round of Alendronate Atypical Fractures Dr. Gregory Curfman, MD writes on the chronological legal progress of a lawsuit stemming from rare instances of atypical femoral fractures associated with bisphosphonate (alendronate) use. https://t.co/6Ipvw7tcKr https://t.co/VNrMg88AsH

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×